

## Curriculum Vitae

Personal information **Jaana Vesterinen**

### Work experience

1. Employer: Finnish Medicines Agency (Fimea)
  - Start date: 012018
  - End date:
  - Position: Head of Section
  - Activities: Head of Laboratory section, quality control of medicines, both chemical and biological. Assessment of biological medicines, particularly bioanalytics. Active role in European Pharmacopoeia, particularly related to biological medicines. Active role in the European Official Medicines Control Laboratory \_ network.
  - Country: Finland
2. Employer: Finnish Medicines Agency (Fimea)
  - Start date: 062008
  - End date: 122017
  - Position: Senior Researcher
  - Activities: Quality control of medicines, expert field especially on biological testing and assessment of biologicals.
  - Country: Finland
3. Employer: Council of Europe, EDQM
  - Start date: 082012
  - End date: 022013
  - Position: Scientific officer
  - Activities: Scientific secretary of expert groups on the biological section of European Pharmacopoeia
  - Country: France
4. Employer: Academy of Finland
  - Start date: 062003
  - End date: 052008
  - Position: Post doctoral research fellow, PI
  - Activities: Biomedical research, neurodegenerative diseases.
  - Country: Finland
5. Employer: University of Helsinki
  - Start date: 091989
  - End date: 052003
  - Position: Research fellow, lecturer
  - Activities: Biomedical research and lecturing, mainly in the medical faculty but also in the faculty of biosciences
  - Country: Finland

### Education and training

1. Subject: University of Helsinki
  - Start date: 061998
  - End date:
  - Qualification: Docent (adjunct professor) of Biochemistry
  - Organisation: Multidisciplinary research in the field of biomedicine, on neurodegenerative diseases.
  - Country: Finland
2. Subject: University of Helsinki
  - Start date: 061997
  - End date:
  - Qualification: PhD in Biochemistry
  - Organisation: Multidisciplinary research in the field of biomedicine, on neurodegenerative diseases.
  - Country: Finland
3. Subject: University of Helsinki
  - Start date: 051989
  - End date:
  - Qualification: MSc in Biochemistry
  - Organisation: Basic education in biochemistry and related sciences.
  - Country: Finland

### Additional information

#### Publications

More than 70 peer reviewed publications in the field of biology and biomedicine (published on maiden name Jaana Tyynelä). Selected, most important publications (Tyynelä J) Tyynelä J, Sohar I, Sleat DE, Gin RM, Donnelly RJ, Baumann M, Haltia M, Lobel P (2000): A mutation in cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration. EMBO J, 19:2786-92. IF 13.51 Siintola E, Partanen S, Stromme P, Haapanen A, Haltia M, Maehlen J, Lehesjoki AE, Tyynela J (2006) Cathepsin D deficiency underlies congenital human neuronal ceroid\_lipofuscinosis. Brain, 129:1438-45 IF 9.49 Jacobs S, Ruusuvuori E, Sipilä ST, Haapanen A, Damkier HH, Kurth I, Hentschke M, Schweizer M, Rudhard Y, Laatikainen L, Tyynelä J, Praetorius J, Voipio J, Hübner CA (2008): Targeted gene disruption reveals important roles for Slc4a10 in cerebrospinal fluid production and neuronal excitability, PNAS, 105:311-6 IF 9.43 Åberg L, Talling M, Härkönen T, Lönnqvist T, Knip M, Alen R, Rantala H,

Tyynelä J (2008): Intermittent prednisolone and autoantibodies to GAD65 in juvenile neuronal ceroid lipofuscinoses, *Neurology*, 70:1218-20 IF 8.17 Khurana V, Elson\_Schwab I, Fulga TA, Sharp KA, Loewen CA, Mulkearns E, Tyynelä J, Scherzer CR, Feany MB (2010): Lysosomal Dysfunction Promotes Cleavage and Neurotoxicity of Tau In Vivo. *PLoS Genet*, 6: e1001026. IF 9.53 Koch S, Scifo E, Rokka A, Trippner P, Lindfors M, Korhonen R, Corthals G, Virtanen I, Lalowski M, Tyynelä J (2013): Cathepsin D deficiency induces cytoskeletal changes and affects cell migration pathways in the brain. *Neurobiol Dis*, 50:107-19 IF 5.6 Shyng C, Nelvagal HR, Dearborn JT, Tyynelä J, Schmidt RE, Sands MS, Cooper JD (2017): Synergistic effects of treating the spinal cord and brain in CLN1 disease. *Proc Natl Acad Sci U S A*. 118:114:E5920-E5929. IF 9.7 Tyynelä J, Lehesjoki AE (2019) Kufs or not Kufs: challenging diagnostics of a rare adult-onset neurodegenerative disease. *Brain*. 142:2-5. IF 11.8

## Projects

Being employed in an official medicines control laboratory, I am actively involved in quality control of biological medicines. Hence, I have a strong interest in developing regulatory surveillance programs within the OMCL network and in developing regulatory standards by participation in EDQM European Pharmacopoeia activities on biological medicines.

In addition, I have long experience in academic research projects on mechanisms of neurodegeneration, as a principal investigator with competitive funding. Particular interest includes neurodegenerative diseases, particularly neuronal ceroid-lipofuscinoses, and Alzheimer. Research on disease models, including large (sheep, dogs) and small (mice) animal models of neurodegeneration, as well as invertebrates (fly) and cell models of neurodegeneration.

## Memberships

2010-2013 Advisory Board of FINNPROT, member of 2010-2013 European Pharmacopoeia Group of Experts No. 6 (Biological products), EDQM, member of 2012- Chair of European Pharmacopoeia Raw materials for the production of cellular and gene transfer products Working Party 2013- 2017 European Pharmacopoeia P4Bio Working party (Biological products), EDQM, member of 2017- Chair of European Pharmacopoeia Monoclonal antibody working party, EDQM 2017- Reference standard influence group, EDQM, member of 2018- OMCL network's CAP Advisory board, member of 2019- OMCL network's CAP Advisory board, chair

## Other Relevant Information